Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression

Clinical Cancer Research

Volumn 18, Issue 16, 2012, Pages 4291-4302

  Chen, James L ^a   Li, Jianrong ^b,c   Kiriluk, Kyle J ^a   Rosen, Alex M ^a   Paner, Gladell P ^a   Antic, Tatjana ^a   Lussier, Yves A ^b,c   Vander Griend, Donald J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c University of Illinois at Chicago   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOX PROTEIN;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE REGULATORY NETWORK; HOXA9 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAK GENE; MAJOR CLINICAL STUDY; MALE; MEIS1 GENE; MEIS2 GENE; NUCLEOTIDE SEQUENCE; PBX1 GENE; PI3K GENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN PROTEIN INTERACTION; SEMINAL VESICLE CANCER; SEMINAL VESICLE DISEASE; STAINING; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

DISEASE PROGRESSION; DNA-BINDING PROTEINS; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM PROTEINS; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN INTERACTION MAPPING; PROTEIN INTERACTION MAPS; PROTO-ONCOGENE PROTEINS; RECURRENCE; SEMINAL VESICLES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84865095179     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0373     Document Type: Article

References (38)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
2. Huggins CS, Stephens RC, Hodges CV. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209-23.
3. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69.
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
5. Curry PT, Atherton RW. Seminal vesicles: development, secretory products, and fertility. Arch Androl 1990;25:107-13.
6. Cunha GR, Alarid ET, Turner T, Donjacour AA, Boutin EL, Foster BA. Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors. J Androl 1992;13:465-75.
7. Moens CB, Selleri L. Hox cofactors in vertebrate development. Dev Biol 2006;291:193-206.
8. Azcoitia V, Aracil M, Martinez AC, Torres M. The homeodomain protein Meis1 is essential for definitive hematopoiesis and vascular patterning in the mouse embryo. Dev Biol 2005;280:307-20.
9. Ota T, Asahina H, Park SH, Huang Q, Minegishi T, Auersperg N, et al. HOX cofactors expression and regulation in the human ovary. Reprod Biol Endocrinol 2008;6:49.
10. Moskow JJ, Bullrich F, Huebner K, Daar IO, Buchberg AM. Meis1, a PBX1-related homeobox gene involved in myeloid leukemia in BXH-2 mice. Mol Cell Biol 1995;15:5434-43.
11. Shen WF, Rozenfeld S, Kwong A, Kom ves LG, Lawrence HJ, Largman C. HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells. Mol Cell Biol 1999;19:3051-61.
12. Geerts D, Revet I, Jorritsma G, Schilderink N, Versteeg R. MEIS homeobox genes in neuroblastoma. Cancer Lett 2005;228:43-50.
13. Wang GG, Pasillas MP, Kamps MP. Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes. Mol Cell Biol 2006;26:3902-16.
14. Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. Nat Rev Cancer 2010;10:361-71.
15. Gao J, Arnold JT, Isaacs JT. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 2001;61:5038-44.
16. Vander Griend DJ, Karthaus WK, Dalrymple S, Meeker AK, De Marzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer initiating cells. Cancer Res 2008;68:9703-11.
17. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 2007;3:11-7.
18. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
19. Thompson M, Lapointe J, Choi YL, Ong DE, Higgins JP, Brooks JD, et al. Identification of candidate prostate cancer genes through comparative expression-profiling of seminal vesicle. Prostate 2008;68:1248-56.
20. Cai CSM, Febbo PG, Balk SP. Expression data for primary localized prostate cancer versus castration-resistant bone metastatic prostate cancer. 2011. Available from: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE32269.
21. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22:2790-9.
22. Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 2010;3:8.
23. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
24. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004;113:913-23.
25. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
26. Chen J, Sam L, Huang Y, Lee Y, Li J, Liu Y, et al. Protein interaction network underpins concordant prognosis among heterogeneous breast cancer signatures. J Biomed Inform 2010;43:385-96.
27. Chen JL, Li J, Stadler WM, Lussier YA. Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence. J Am Med Inform Assoc 2011;18:392-402.
28. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nat Rev Cancer 2004;4:177-83.
29. Kirk RE. Experimental design: procedure for behavioral science. 2nd ed. Monterey, CA: Brooks/Cole; 1982.
30. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-504.
31. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
32. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72.
33. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25:25-9.
34. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22:2790-9.
35. Epstein JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol 2004;17:307-15.
36. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012;366:141-9.
37. Zhang H, Dong Y, Zhao H, Brooks JD, Hawthorn L, Nowak N, et al. Microarray data mining for potential selenium targets in chemoprevention of prostate cancer. Cancer Genomics Proteomics 2005;2:97-114.
38. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.